Skip to main content

Table 7 Prognostic factors of overall survival

From: Optimal radiotherapy for patients with internal mammary lymph node metastasis from breast cancer

Characteristics5-year OSUnivariate
p-value
Multivariate
p-value
HR
(95% CI)
Age≤40 years (n = 38)94.6%0.0070.0090.132(0.029–0.609)
> 40 years (n = 46)75.4%
Tumor subtype1)Non-TNBC (n = 54)92.0%0.0160.0030.167(0.051–0.548)
TNBC (n = 30)70.0%
cT stages1–2 (n = 47)87.0%0.2320.0673.049(0.925–10.054)
3–4 (n = 37)80.1%
cN stages2b or 3b (n = 63)83.3%0.492
3c (n = 21)85.7%
Malignant cells on FNABx of the IMN(−) or unknown (n = 44)84.5%0.557
(+) (n = 40)83.4%
Extent of IMNSingle ICS (n = 37)89.1%0.0450.8450.890(0.275–2.880)
Multiple ICS (n = 47)79.9%
IMN long diameter< 1.0 cm (n = 42)92.7%0.0530.0521.621(0.318–8.255)
≥1.0 cm (n = 42)75.7%
Neoadjuvant chemotherapyPerformed (n = 66)82.9%0.493
Not performed (n = 18)87.8%
Axillary surgeryALND (n = 74)83.2%0.556
SLNB (n = 10)90.0%
EQD2 of the IMN2)50.0–63.5 Gy (n = 35)85.3%0.926
63.6–70.4 Gy (n = 49)82.8%
  1. 1)TNBC was defined as tumors that were negative for the estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 on immunohistochemical staining of the breast tumor
  2. 2)Radiotherapy dose was calculated using the EQD2 assuming the α/β ratio of 3.5 Gy
  3. Abbreviations: OS Overall survival, TNBC Triple-negative breast cancer, FNABx Fine needle aspiration biopsy, IMN Internal mammary node, ICS Intercostal space, ALND Axillary lymph node dissection, SLNB Sentinel lymph node biopsy, HR Hazard ratio, CI Confidence interval, EQD2 Biologically equivalent dose in 2 Gy fractions